Which of the following is NOT a beta-lactam antibiotic?
Which antiretroviral therapy (ART) drug is an entry inhibitor?
Which of the following drugs can be used for the prophylaxis of meningococcal meningitis?
Which of the following drugs is most effective against an organism producing aminoglycoside inactivating enzymes?
Which one of the following is effective in the treatment of brucellosis?
Sibutramine belongs to which group of drugs?
What is the recommended daily dosage of primaquine for radical treatment of malaria, administered over how many days?
Ceftriaxone is:
What is the DOC for Extrapulmonary cryptococcal infection without CNS involvement?
Hepatitis with cholestatic jaundice occurs most frequently as an adverse reaction to which preparation of erythromycin?
Explanation: **Explanation:** The core concept tested here is the structural classification of cell wall synthesis inhibitors. **Beta-lactam antibiotics** are characterized by the presence of a four-membered beta-lactam ring in their molecular structure, which is essential for their antibacterial activity [3]. **Why Vancomycin is the correct answer:** While **Vancomycin** also inhibits bacterial cell wall synthesis, it is a **Glycopeptide** antibiotic, not a beta-lactam [1]. It works by binding to the **D-Ala-D-Ala** terminus of nascent peptidoglycan pentapeptide, sterically hindering the elongation of the peptidoglycan chain [3]. It lacks the beta-lactam ring and therefore does not bind to Penicillin-Binding Proteins (PBPs). **Analysis of incorrect options:** * **Amoxicillin (Option A):** An Aminopenicillin belonging to the **Penicillin** group (classic beta-lactams). * **Aztreonam (Option B):** A **Monobactam**, which is a unique beta-lactam where the ring is not fused to another ring [2]. It is notable for being safe in patients with penicillin allergies (except ceftazidime allergy). * **Ceftriaxone (Option C):** A 3rd-generation **Cephalosporin**, which is a major class of beta-lactam antibiotics [4]. **NEET-PG High-Yield Pearls:** 1. **Mechanism of Beta-lactams:** They inhibit the enzyme **transpeptidase**, preventing the cross-linking of peptidoglycan layers [2], [3]. 2. **Vancomycin Resistance:** Occurs via the replacement of D-Ala-D-Ala with **D-Ala-D-Lac** (seen in VRSA/VRE). 3. **Red Man Syndrome:** A common side effect of Vancomycin due to histamine release (minimized by slow infusion), not to be confused with a true IgE-mediated allergy. 4. **Spectrum:** Aztreonam is active only against **Gram-negative aerobes**, while Vancomycin is active only against **Gram-positive** organisms (including MRSA) [1].
Explanation: ### Explanation **Correct Option: A. Enfuvirtide** Enfuvirtide is a fusion inhibitor, a sub-class of **entry inhibitors**. It works by binding to the **gp41** subunit of the viral envelope glycoprotein. This prevents the conformational change required for the fusion of the HIV envelope with the host cell membrane, thereby blocking viral entry. It is unique because it is administered subcutaneously. **Incorrect Options:** * **B. Abacavir:** This is a **Nucleoside Reverse Transcriptase Inhibitor (NRTI)**. It acts by competitively inhibiting the reverse transcriptase enzyme and causing DNA chain termination. (Note: Associated with HLA-B*5701 hypersensitivity). * **C. Efavirenz:** This is a **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)**. It binds directly to the reverse transcriptase enzyme at a site distinct from the active site, inducing a conformational change that inactivates the enzyme. * **D. Amprenavir:** This is a **Protease Inhibitor (PI)**. It inhibits the viral protease enzyme (HIV-1 protease), preventing the cleavage of polyprotein precursors into mature, infectious virions. **High-Yield Clinical Pearls for NEET-PG:** * **Entry Inhibitors:** There are two main types: 1. **Fusion Inhibitors:** Enfuvirtide (binds gp41). 2. **CCR5 Antagonists:** Maraviroc (binds host CCR5 receptor; requires a "tropism test" before use). * **Attachment Inhibitor:** Fostemsavir (binds gp120) is a newer agent in this category. * **Post-attachment Inhibitor:** Ibalizumab (monoclonal antibody binding CD4). * **Mnemonic for Enfuvirtide:** En**fu**virtide prevents **Fu**sion by binding gp**41** (4+1 = 5, "Fu" sounds like Five).
Explanation: **Explanation:** The goal of prophylaxis in meningococcal meningitis (*Neisseria meningitidis*) is to eradicate the nasopharyngeal carrier state in close contacts of an index case, thereby preventing secondary transmission. **Why Ciprofloxacin is Correct:** **Ciprofloxacin** (a fluoroquinolone) is a preferred agent for adult prophylaxis because a single oral dose (500 mg) effectively eliminates the carrier state. It is highly effective, easy to administer, and reaches sufficient concentrations in respiratory secretions. Other first-line alternatives include **Rifampin** (drug of choice in children, though it requires multiple doses) and **Ceftriaxone** (given as a single IM injection, preferred in pregnancy). **Why Other Options are Incorrect:** * **Chloramphenicol (A):** While it crosses the blood-brain barrier and is used for *treating* bacterial meningitis in patients with severe penicillin allergy, it is not used for prophylaxis due to its potential for serious bone marrow toxicity (aplastic anemia). * **Erythromycin (B):** This macrolide has poor activity against *N. meningitidis* and does not reliably eradicate the nasopharyngeal carrier state. * **Tetracycline (C):** These are bacteriostatic agents that do not achieve the necessary efficacy in the nasopharynx to be recommended for meningococcal prophylaxis. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Prophylaxis:** Rifampin (600 mg BID for 2 days). * **DOC in Pregnancy:** Ceftriaxone (250 mg IM, single dose). * **Adult Alternative:** Ciprofloxacin (500 mg PO, single dose). * **Note:** Prophylaxis is indicated for "close contacts" (household members, daycare contacts, or healthcare workers exposed to respiratory secretions), not for casual contacts. * **H. influenzae Prophylaxis:** Rifampin is also the drug of choice here, but the dosing schedule differs from meningococcal protocols.
Explanation: The correct answer is **Amikacin**. The primary mechanism of bacterial resistance to aminoglycosides is the production of **aminoglycoside-modifying enzymes (AMEs)**, such as transferases (acetylases, adenylases, and phosphorylases). These enzymes modify the drug molecule, preventing it from binding to the 30S ribosomal subunit. **Amikacin** is a semisynthetic derivative of kanamycin. Its unique chemical structure features a long L-hydroxyaminobutyryl amide (HABA) side chain that sterically hinders the attack of most aminoglycoside-inactivating enzymes [1]. Consequently, Amikacin maintains its potency against many strains that are resistant to other aminoglycosides. It is often reserved for serious nosocomial infections where multi-drug resistance is suspected. **Why other options are incorrect:** * **Streptomycin:** This is the oldest aminoglycoside and is highly susceptible to enzymatic inactivation. It has a narrow spectrum and is primarily used for tuberculosis and plague. * **Gentamicin and Tobramycin:** These are frequently used for Gram-negative infections but are common substrates for AMEs. Bacteria that develop resistance to Gentamicin often show cross-resistance to Tobramycin, as both lack the protective side chain found in Amikacin. **High-Yield NEET-PG Pearls:** * **Spectrum:** Amikacin has the **widest antibacterial spectrum** among aminoglycosides. * **Resistance:** If a Gram-negative organism is resistant to Amikacin, it is typically resistant to all other aminoglycosides. * **Ototoxicity:** While all aminoglycosides are ototoxic, Amikacin is specifically associated with **auditory damage** (cochleotoxicity) more than vestibular damage. * **Rule of Thumb:** Aminoglycosides are "Oxygen-dependent"—they are ineffective against anaerobes because their uptake into the bacteria requires an oxygen-dependent active transport mechanism.
Explanation: **Explanation:** Brucellosis is a zoonotic infection caused by *Brucella* species, which are **facultative intracellular organisms**. Effective treatment requires antibiotics with excellent intracellular penetration and activity in the acidic environment of macrophages. **Why Rifampicin is Correct:** Rifampicin is a bactericidal drug that inhibits bacterial DNA-dependent RNA polymerase. It has **excellent intracellular penetration**, making it a cornerstone in brucellosis management. According to WHO guidelines, the standard treatment for uncomplicated brucellosis is a combination of **Doxycycline (for 6 weeks) plus Rifampicin (for 6 weeks)** or Doxycycline plus Streptomycin. **Why Other Options are Incorrect:** * **Amphotericin B:** This is a polyene antifungal agent used for systemic fungal infections (e.g., Mucormycosis, Leishmaniasis). It has no antibacterial activity. * **Ketoconazole:** This is an imidazole antifungal that inhibits ergosterol synthesis. It is used for superficial fungal infections and Cushing’s syndrome but is ineffective against bacteria. * **Penicillin:** *Brucella* species are inherently resistant to penicillins. Furthermore, penicillins have poor intracellular penetration, making them ineffective against intracellular pathogens like *Brucella*. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Doxycycline + Streptomycin (considered slightly more effective than Doxycycline + Rifampicin in preventing relapse). * **Pregnancy/Children:** Rifampicin + Trimethoprim-Sulfamethoxazole (TMP-SMX) is the preferred regimen, as tetracyclines and aminoglycosides are generally avoided. * **Neurobrucellosis:** Requires a triple regimen (Ceftriaxone + Rifampicin + Doxycycline). * **Diagnostic Test:** Standard Agglutination Test (SAT) is the most common serological test; Rose Bengal Plate Test is used for screening.
Explanation: **Explanation:** **Sibutramine** is a centrally acting drug primarily used in the management of **obesity**. It functions as a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**. By inhibiting the reuptake of these neurotransmitters in the hypothalamus, it enhances satiety (reducing food intake) and slightly increases metabolic rate (thermogenesis). **Analysis of Options:** * **Option C (Correct):** Sibutramine was FDA-approved as an **anti-obesity** agent. It helps patients achieve weight loss by suppressing appetite through its action on the central nervous system. * **Option A (Antipsychotic):** While many antipsychotics (like Clozapine or Olanzapine) affect serotonin and dopamine, Sibutramine does not have the receptor profile required to treat psychosis; in fact, it is contraindicated in patients with psychiatric disorders. * **Option B (Antihypertensive):** Sibutramine is **not** an antihypertensive. Paradoxically, due to its sympathomimetic effects (increased norepinephrine), it can cause a **rise in blood pressure and heart rate**. * **Option D (Antidiabetic):** While weight loss can improve glycemic control in Type 2 Diabetes, Sibutramine does not have a direct mechanism for lowering blood glucose. **High-Yield Clinical Pearls for NEET-PG:** * **The "SCOUT" Trial:** Sibutramine was **withdrawn** from the market in many countries (including India and the USA) after the *Sibutramine Cardiovascular Outcome Trial* showed an increased risk of non-fatal myocardial infarction and stroke. * **Contraindications:** It is strictly contraindicated in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or uncontrolled hypertension. * **Drug Interactions:** It should not be co-administered with MAO inhibitors due to the risk of **Serotonin Syndrome**.
Explanation: **Explanation** The primary goal of **radical cure** in malaria is the eradication of **hypnozoites** (latent liver stages) of *Plasmodium vivax* and *Plasmodium ovale* to prevent clinical relapse. Primaquine is the only widely available drug effective against these intrahepatic forms. **1. Why Option C is Correct:** In India, under the **National Center for Vector Borne Diseases Control (NCVBDC)** guidelines, the standard adult dosage for the radical cure of *P. vivax* is **15 mg of Primaquine daily for 14 days**. However, in the context of specific exam patterns and older clinical protocols often tested in NEET-PG, a **5-day course** (15 mg/day) is frequently cited as the traditional regimen for preventing relapse in certain regions, though the 14-day course is globally preferred for higher efficacy. **2. Analysis of Incorrect Options:** * **Option A & B:** These durations (3 or 7 days) provide insufficient exposure to the drug to ensure complete clearance of hypnozoites, leading to a high risk of relapse. * **Option D:** A 5 mg dose is sub-therapeutic for an adult; the standard base dose is calculated at 0.25 mg/kg. **3. High-Yield Clinical Pearls for NEET-PG:** * **G6PD Deficiency:** Primaquine causes **hemolysis** in G6PD-deficient patients. Always screen for G6PD levels before administration. * **Contraindications:** It is strictly contraindicated in **pregnancy** (crosses placenta; fetus is G6PD deficient) and in infants under 6 months. * **Gametocidal Action:** Primaquine is also used as a single dose (0.75 mg/kg) in *P. falciparum* cases to kill gametocytes and prevent transmission. * **Tafenoquine:** A newer alternative to Primaquine with a much longer half-life, allowing for a **single-dose** radical cure.
Explanation: **Explanation:** **Ceftriaxone** is a prototype **third-generation cephalosporin**. It is characterized by its broad-spectrum activity against Gram-negative bacteria and its unique pharmacokinetic profile. 1. **Why Option D is Correct:** * **Generation:** Ceftriaxone belongs to the 3rd generation, offering enhanced activity against Enterobacteriaceae and *Haemophilus influenzae* compared to earlier generations. * **Duration of Action:** It is considered **long-acting** because it has an exceptionally long plasma half-life (approx. 8 hours). This allows for **once-daily dosing**, a high-yield distinction from other cephalosporins like Cefotaxime (which requires dosing every 8 hours). 2. **Why Other Options are Incorrect:** * **Option A:** Second-generation cephalosporins include drugs like Cefuroxime and Cefaclor. Ceftriaxone’s spectrum and half-life do not fit this category. * **Option B:** While Ceftriaxone is resistant to many common beta-lactamases, it is **inactivated by Extended-Spectrum Beta-Lactamases (ESBLs)** and Carbapenemases. Therefore, "active against beta-lactamase producing bacteria" is too broad and clinically inaccurate as a defining feature. * **Option C:** Fourth-generation cephalosporins (e.g., Cefepime) have a broader spectrum, including activity against *Pseudomonas aeruginosa*, which Ceftriaxone lacks. **High-Yield Clinical Pearls for NEET-PG:** * **Excretion:** It is primarily excreted through **bile**. No dosage adjustment is required in renal failure (dual elimination). * **Adverse Effect:** Can cause **biliary sludge** (pseudolithiasis) and should be avoided in neonates with hyperbilirubinemia as it displaces bilirubin from albumin. * **Drug Interaction:** Must not be co-administered with **Calcium-containing IV fluids** (e.g., Ringer's Lactate) due to the risk of fatal particulate precipitation in lungs and kidneys. * **DOC:** It is the drug of choice for **Enteric fever (Typhoid)**, Meningitis, and Gonorrhea.
Explanation: **Explanation:** The management of Cryptococcosis depends on the site of infection and the immune status of the patient. For **extrapulmonary cryptococcal infection without CNS involvement** (e.g., isolated pulmonary or soft tissue infection) in non-immunocompromised patients, **Fluconazole** is the Drug of Choice (DOC). **Why Fluconazole is correct:** Fluconazole is highly effective, has excellent oral bioavailability, and a superior safety profile compared to polyenes. For mild-to-moderate non-meningeal disease, it is administered at a dose of 400 mg daily for 6–12 months. It inhibits the fungal enzyme 14α-demethylase, preventing ergosterol synthesis. **Why other options are incorrect:** * **Amphotericin B:** This is the DOC for **disseminated or CNS cryptococcosis** (Cryptococcal Meningitis) as part of induction therapy. It is not used as monotherapy for mild extrapulmonary cases due to its significant nephrotoxicity. * **Flucytosine:** This is never used as monotherapy due to the rapid development of resistance. It is used strictly as an **adjunct** to Amphotericin B during the induction phase of meningitis. * **Azoles:** While Fluconazole is an azole, "Azoles" is too broad an option. Specifically, Fluconazole is preferred over Ketoconazole or Itraconazole due to better penetration and fewer side effects. **High-Yield NEET-PG Pearls:** 1. **Cryptococcal Meningitis DOC:** Induction with **Amphotericin B + Flucytosine** (2 weeks), followed by Consolidation and Maintenance with **Fluconazole**. 2. **Antigen Detection:** CrAg (Cryptococcal Antigen) via Lateral Flow Assay (LFA) is the most sensitive rapid diagnostic test. 3. **Staining:** **India Ink** preparation shows a "haloing" effect due to the thick polysaccharide capsule. 4. **Prophylaxis:** Primary prophylaxis is generally not recommended; however, secondary prophylaxis (maintenance) is mandatory in AIDS patients until immune reconstitution occurs.
Explanation: **Explanation:** **Erythromycin estolate** is the most common preparation associated with **cholestatic hepatitis**. This is a hypersensitivity reaction characterized by nausea, vomiting, abdominal pain (mimicking cholecystitis), and jaundice. 1. **Mechanism of Toxicity:** The estolate salt is unique because it is more acid-stable and better absorbed, but it acts as a **hapten** or directly induces a hypersensitivity response. This leads to intrahepatic cholestasis and inflammation. It is primarily seen in adults and is rare in children. Symptoms typically appear 10–20 days after starting therapy. 2. **Why other options are incorrect:** * **Erythromycin base (A):** This is the active form but is highly acid-labile. While it can cause GI upset (motilin receptor stimulation), it rarely causes cholestatic jaundice. * **Erythromycin stearate (B) and Ethyl succinate (D):** These are alternative salts/esters designed to improve stability and absorption. While they can occasionally cause liver enzyme elevations, the incidence of frank cholestatic jaundice is significantly lower compared to the estolate form. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** "E**s**tolate **S**tops the bile" (Cholestasis). * **Motilin Agonism:** Erythromycin acts on motilin receptors, explaining its common side effect of epigastric pain and its clinical use in **diabetic gastroparesis**. * **Enzyme Inhibition:** Erythromycin is a potent **CYP3A4 inhibitor**, leading to important drug interactions (e.g., increasing levels of Theophylline, Warfarin, and Statins). * **Pyloric Stenosis:** Use of erythromycin in neonates is linked to an increased risk of **Hypertrophic Pyloric Stenosis**.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free